8-K: PetMeds Reports Q2 Revenue Decline, Faces Nasdaq Delisting Threat

PetMed Express, Inc. announced preliminary Q2 2025 revenues significantly below prior year figures and received a Nasdaq notice for continued delinquency in financial filings.

Summary

• Preliminary estimated net sales for Q2 2025 (ended September 30, 2025) are projected to be between $43.4 million and $44.5 million, a decrease from $58.0 million (restated) in the prior year period.
• Preliminary estimated net sales for the six months ended September 30, 2025, are projected to be between $94.5 million and $95.6 million, down from $124.3 million (restated) in the prior year period.
• The company is unable to provide estimates for operating or net income due to an ongoing analysis of an anticipated goodwill impairment charge.
• PetMed Express, Inc. received a notice from Nasdaq on November 12, 2025, indicating non-compliance with Listing Rule 5250(c)(1) due to delays in filing its Q1 and Q2 2025 Form 10-Qs.
• The company was previously delinquent in filing its Form 10-K for the fiscal year ended March 31, 2025.
• Nasdaq's exception period for regaining compliance, if granted, will be limited to 180 calendar days from the initial 10-K due date, or December 29, 2025.
• The company must submit an updated plan to regain compliance by November 28, 2025.
• The Nasdaq notice has no immediate effect on the listing of the company's common stock.
• As of September 30, 2025, the company held $36.1 million in cash and had no debt.

Sentiment

Score: 2

Explanation: The filing indicates significant financial deterioration with a substantial revenue decline and inability to provide income estimates due to potential goodwill impairment. Coupled with severe corporate governance issues due to repeated financial reporting delinquencies and a Nasdaq non-compliance notice, the overall sentiment is highly negative, reflecting serious operational and financial challenges.

Positives

• The company maintains a strong cash position of $36.1 million as of September 30, 2025.
• The company has no outstanding debt.
• The Nasdaq notice has no immediate effect on the listing of the company's common stock.
• Management is working diligently to complete and file the overdue financial reports.

Negatives

• Preliminary estimated net sales for Q2 2025 declined significantly to $43.4 million $44.5 million from $58.0 million in the prior year.
• Preliminary estimated net sales for the six months ended September 30, 2025, decreased to $94.5 million $95.6 million from $124.3 million in the prior year.
• The company is unable to provide estimates for operating income or net income due to an ongoing analysis of an anticipated goodwill impairment charge.
• The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to delays in filing its Q1 and Q2 2025 Form 10-Qs.
• This is a continued delinquency, following a delay in filing the Form 10-K for the fiscal year ended March 31, 2025.
• The maximum exception period to regain compliance from Nasdaq is limited to 180 calendar days from the initial 10-K due date, or December 29, 2025.

Risks

• The company's ability to complete the filing of its Q1 10-Q and Q2 10-Q within the anticipated time period.
• The company's ability to regain compliance with Nasdaq listing standards.
• The time and effort required to complete and file the company's financial statements and Form 10-Qs for its fiscal quarters ending June 30, 2025, and September 30, 2025.
• Future results may be impacted by other risk factors listed in previous SEC filings, including the Annual Report on Form 10-K for the year ended March 31, 2025.
• An anticipated goodwill impairment charge, previously discussed in the Annual Report on Form 10-K, could negatively impact financial results.

Future Outlook

The company intends to work diligently to complete and file its Q1 10-Q and Q2 10-Q as promptly as possible to regain compliance with Nasdaq listing rules. However, it provides no assurances as to the timing of these filings or its ability to regain compliance.

Management Comments

• "The Company continues to work diligently to complete its Q1 10-Q and Q2 10-Q and intends to file them as promptly as possible to regain compliance with the Listing Rule."
• "While the Company can provide no assurances as to timing..."

Industry Context

The pet healthcare sector, particularly online pharmacies, has seen increased competition and evolving consumer preferences. A significant revenue decline for a pioneer like PetMeds, coupled with financial reporting delays, could indicate challenges in adapting to market dynamics or increased competitive pressures from larger e-commerce players or specialized pet health platforms. The inability to provide income estimates due to a potential goodwill impairment suggests underlying business performance issues that may be broader than just sales.

Comparison to Industry Standards

• The reported preliminary net sales decline of approximately 23-25% year-over-year for Q2 2025 (from $58.0M to $43.4M-$44.5M) is significantly worse than the general growth trends observed in the broader pet care industry, which has historically shown resilience and steady growth. For example, major pet retailers and online platforms often report single-digit to low double-digit revenue growth.
• The inability to provide operating or net income estimates due to an ongoing goodwill impairment analysis is a red flag, suggesting potential overvaluation of past acquisitions or significant deterioration in the value of its business units, which is not typical for healthy, growing companies in the sector.
• The repeated delinquency in filing periodic financial reports (10-K, Q1 10-Q, Q2 10-Q) is a severe corporate governance issue that falls far below industry standards for publicly traded companies, which are expected to maintain timely and transparent financial reporting. This contrasts sharply with well-managed peers who consistently meet SEC deadlines.

Stakeholder Impact

• Shareholders: Face increased risk of stock delisting, significant uncertainty regarding financial performance, and potential for further share price decline due to poor results and governance issues.
• Customers: Potential impact on service or product availability if financial instability affects operations, though not directly stated.
• Employees: Uncertainty regarding job security and company stability due to financial and operational challenges.
• Suppliers/Creditors: Increased risk perception due to financial reporting delays and declining revenues, potentially impacting credit terms or relationships.
• Regulatory Authorities (SEC/Nasdaq): Continued scrutiny and potential enforcement actions if compliance is not regained.

Next Steps

• Complete and file the Quarterly Report on Form 10-Q for the period ended June 30, 2025 (Q1 10-Q).
• Complete and file the Quarterly Report on Form 10-Q for the period ended September 30, 2025 (Q2 10-Q).
• Submit an updated plan to Nasdaq to regain compliance by November 28, 2025.
• Address the ongoing analysis of an anticipated goodwill impairment charge.

Key Dates

Recommendation

The filing reveals a substantial year-over-year revenue decline (23-25%) for Q2 2025, coupled with the inability to provide operating or net income estimates due to a potential goodwill impairment. This indicates severe underlying business performance issues. Furthermore, the company is in repeated non-compliance with Nasdaq listing rules due to multiple delinquent financial filings (10-K, Q1 10-Q, Q2 10-Q), facing a strict deadline of December 29, 2025, to regain compliance. These factors point to significant operational, financial, and corporate governance failures, creating high uncertainty and risk for investors, making the stock a strong sell.

Keywords

PetMed Express, PETS, Nasdaq non-compliance, Q2 2025 earnings, revenue decline, financial delinquency, pet healthcare, online pharmacy, goodwill impairment, SEC filing